These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26751560)

  • 1. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis.
    Zhang C; Liu J; Zhao Y; Yue X; Zhu Y; Wang X; Wu H; Blanco F; Li S; Bhanot G; Haffty BG; Hu W; Feng Z
    Elife; 2016 Jan; 5():e10727. PubMed ID: 26751560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
    Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
    Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function.
    Hu W; Zhang C; Wu R; Sun Y; Levine A; Feng Z
    Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7455-60. PubMed ID: 20378837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma.
    Yu D; Shi X; Meng G; Chen J; Yan C; Jiang Y; Wei J; Ding Y
    Oncotarget; 2015 Apr; 6(10):7619-31. PubMed ID: 25844758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species.
    Suzuki S; Tanaka T; Poyurovsky MV; Nagano H; Mayama T; Ohkubo S; Lokshin M; Hosokawa H; Nakayama T; Suzuki Y; Sugano S; Sato E; Nagao T; Yokote K; Tatsuno I; Prives C
    Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7461-6. PubMed ID: 20351271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
    Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
    Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLS2 is protumorigenic in breast cancers.
    Dias MM; Adamoski D; Dos Reis LM; Ascenção CFR; de Oliveira KRS; Mafra ACP; da Silva Bastos AC; Quintero M; de G Cassago C; Ferreira IM; Fidelis CHV; Rocco SA; Bajgelman MC; Stine Z; Berindan-Neagoe I; Calin GA; Ambrosio ALB; Dias SMG
    Oncogene; 2020 Jan; 39(3):690-702. PubMed ID: 31541193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers.
    Basheer HA; Elsalem L; Salem A; Tailor A; Hunter K; Afarinkia K
    Curr Cancer Drug Targets; 2022; 22(2):169-179. PubMed ID: 34951574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and activation mechanism of the human liver-type glutaminase GLS2.
    Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
    Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells.
    Lee YZ; Yang CW; Chang HY; Hsu HY; Chen IS; Chang HS; Lee CH; Lee JC; Kumar CR; Qiu YQ; Chao YS; Lee SJ
    Oncotarget; 2014 Aug; 5(15):6087-101. PubMed ID: 25026281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLS2 Is a Tumor Suppressor and a Regulator of Ferroptosis in Hepatocellular Carcinoma.
    Suzuki S; Venkatesh D; Kanda H; Nakayama A; Hosokawa H; Lee E; Miki T; Stockwell BR; Yokote K; Tanaka T; Prives C
    Cancer Res; 2022 Sep; 82(18):3209-3222. PubMed ID: 35895807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer.
    Lukey MJ; Cluntun AA; Katt WP; Lin MJ; Druso JE; Ramachandran S; Erickson JW; Le HH; Wang ZE; Blank B; Greene KS; Cerione RA
    Cell Rep; 2019 Oct; 29(1):76-88.e7. PubMed ID: 31577957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of glutaminase in cancer.
    Masisi BK; El Ansari R; Alfarsi L; Rakha EA; Green AR; Craze ML
    Histopathology; 2020 Mar; 76(4):498-508. PubMed ID: 31596504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RCC2 is a novel p53 target in suppressing metastasis.
    Song C; Liang L; Jin Y; Li Y; Liu Y; Guo L; Wu C; Yun CH; Yin Y
    Oncogene; 2018 Jan; 37(1):8-17. PubMed ID: 28869598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus.
    Hisada R; Yoshida N; Orite SYK; Umeda M; Burbano C; Scherlinger M; Kono M; Krishfield S; Tsokos GC
    Arthritis Rheumatol; 2022 Jul; 74(7):1204-1210. PubMed ID: 35254008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
    Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
    Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation.
    López de la Oliva AR; Campos-Sandoval JA; Gómez-García MC; Cardona C; Martín-Rufián M; Sialana FJ; Castilla L; Bae N; Lobo C; Peñalver A; García-Frutos M; Carro D; Enrique V; Paz JC; Mirmira RG; Gutiérrez A; Alonso FJ; Segura JA; Matés JM; Lubec G; Márquez J
    Sci Rep; 2020 Feb; 10(1):2259. PubMed ID: 32042057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opposing roles of glutaminase isoforms in determining glioblastoma cell phenotype.
    Szeliga M; Albrecht J
    Neurochem Int; 2015 Sep; 88():6-9. PubMed ID: 25529918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p63 regulates glutaminase 2 expression.
    Giacobbe A; Bongiorno-Borbone L; Bernassola F; Terrinoni A; Markert EK; Levine AJ; Feng Z; Agostini M; Zolla L; Agrò AF; Notterman DA; Melino G; Peschiaroli A
    Cell Cycle; 2013 May; 12(9):1395-405. PubMed ID: 23574722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation.
    Xiang L; Xie G; Liu C; Zhou J; Chen J; Yu S; Li J; Pang X; Shi H; Liang H
    Biochim Biophys Acta; 2013 Dec; 1833(12):2996-3005. PubMed ID: 23954443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.